105 related articles for article (PubMed ID: 38748869)
1. Biological and Clinical Determinants Shaping Heterogeneity in Mantle Cell Lymphoma.
López C; Silkenstedt E; Dreyling M; Beà S
Blood Adv; 2024 May; ():. PubMed ID: 38748869
[TBL] [Abstract][Full Text] [Related]
2. A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome.
Clot G; Jares P; Giné E; Navarro A; Royo C; Pinyol M; Martín-Garcia D; Demajo S; Espinet B; Salar A; Ferrer A; Muntañola A; Aymerich M; Rauert-Wunderlich H; Jaffe ES; Connors JM; Gascoyne RD; Delabie J; López-Guillermo A; Ott G; Wright GW; Staudt LM; Rosenwald A; Scott DW; Rimsza LM; Beà S; Campo E
Blood; 2018 Jul; 132(4):413-422. PubMed ID: 29769262
[TBL] [Abstract][Full Text] [Related]
3. Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes.
Nadeu F; Martin-Garcia D; Clot G; Díaz-Navarro A; Duran-Ferrer M; Navarro A; Vilarrasa-Blasi R; Kulis M; Royo R; Gutiérrez-Abril J; Valdés-Mas R; López C; Chapaprieta V; Puiggros M; Castellano G; Costa D; Aymerich M; Jares P; Espinet B; Muntañola A; Ribera-Cortada I; Siebert R; Colomer D; Torrents D; Gine E; López-Guillermo A; Küppers R; Martin-Subero JI; Puente XS; Beà S; Campo E
Blood; 2020 Sep; 136(12):1419-1432. PubMed ID: 32584970
[TBL] [Abstract][Full Text] [Related]
4. Toward a Risk-Tailored Therapeutic Policy in Mantle Cell Lymphoma.
Condoluci A; Rossi D; Zucca E; Cavalli F
Curr Oncol Rep; 2018 Aug; 20(10):79. PubMed ID: 30132080
[TBL] [Abstract][Full Text] [Related]
5. [Clinical and biological features and prognosis of patients with leukemic non-nodal mantle cell lymphoma].
Chen JW; Wang Y; Yan YT; Xiong WJ; Wang TY; Liu W; Zou DH; Qiu LG; Yi SH
Zhonghua Yi Xue Za Zhi; 2023 Jun; 103(23):1746-1752. PubMed ID: 37305933
[No Abstract] [Full Text] [Related]
6. Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A/B loss, and TP53 mutations: A multi-institutional study.
Streich L; Sukhanova M; Lu X; Chen YH; Venkataraman G; Mathews S; Zhang S; Kelemen K; Segal J; Gao J; Gordon L; Chen Q; Behdad A
Genes Chromosomes Cancer; 2020 Aug; 59(8):484-494. PubMed ID: 32277542
[TBL] [Abstract][Full Text] [Related]
7. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
8. Molecular profiling and management of mantle cell lymphoma.
Ruan J
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):30-40. PubMed ID: 31808882
[TBL] [Abstract][Full Text] [Related]
9. Current Knowledge in Genetics, Molecular Diagnostic Tools, and Treatments for Mantle Cell Lymphomas.
Sethi S; Epstein-Peterson Z; Kumar A; Ho C
Front Oncol; 2021; 11():739441. PubMed ID: 34888236
[TBL] [Abstract][Full Text] [Related]
10. Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management.
Jain P; Wang M
Am J Hematol; 2019 Jun; 94(6):710-725. PubMed ID: 30963600
[TBL] [Abstract][Full Text] [Related]
11. Leukemic Variant of Mantle Cell Lymphoma: Clinical Presentation and Management.
Isaac KM; Portell CA; Williams ME
Curr Oncol Rep; 2021 Jul; 23(9):102. PubMed ID: 34269910
[TBL] [Abstract][Full Text] [Related]
12. Mantle cell lymphoma-Advances in molecular biology, prognostication and treatment approaches.
Silkenstedt E; Dreyling M
Hematol Oncol; 2021 Jun; 39 Suppl 1():31-38. PubMed ID: 34105823
[TBL] [Abstract][Full Text] [Related]
13. Highly sensitive and specific
Federmann B; Frauenfeld L; Pertsch H; Borgmann V; Steinhilber J; Bonzheim I; Fend F; Quintanilla-Martinez L
Haematologica; 2020 Mar; 105(3):754-764. PubMed ID: 31296581
[TBL] [Abstract][Full Text] [Related]
14. Progressive leukemic non-nodal mantle cell lymphoma associated with deletions of TP53, ATM, and/or 13q14.
Chapman-Fredricks J; Sandoval-Sus J; Vega F; Lossos IS
Ann Diagn Pathol; 2014 Aug; 18(4):214-9. PubMed ID: 24852242
[TBL] [Abstract][Full Text] [Related]
15. SOHO State of the Art Updates and Next Questions: Treatment Evolution of Mantle Cell Lymphoma: Navigating the Different Entities and Biological Heterogeneity of Mantle Cell Lymphoma in 2024.
Ip A; Della Pia A; Goy AH
Clin Lymphoma Myeloma Leuk; 2024 Feb; ():. PubMed ID: 38493059
[TBL] [Abstract][Full Text] [Related]
16. Role of SOX11 and Genetic Events Cooperating with Cyclin D1 in Mantle Cell Lymphoma.
Beà S; Amador V
Curr Oncol Rep; 2017 Jun; 19(6):43. PubMed ID: 28466437
[TBL] [Abstract][Full Text] [Related]
17. Mantle cell lymphoma-Update on molecular biology, prognostication and treatment approaches.
Silkenstedt E; Dreyling M
Hematol Oncol; 2023 Jun; 41 Suppl 1():36-42. PubMed ID: 37294961
[TBL] [Abstract][Full Text] [Related]
18. How I manage mantle cell lymphoma: indolent versus aggressive disease.
Wilson MR; Barrett A; Cheah CY; Eyre TA
Br J Haematol; 2023 Apr; 201(2):185-198. PubMed ID: 36807902
[TBL] [Abstract][Full Text] [Related]
19. Smoldering mantle cell lymphoma.
Ye H; Desai A; Zeng D; Nomie K; Romaguera J; Ahmed M; Wang ML
J Exp Clin Cancer Res; 2017 Dec; 36(1):185. PubMed ID: 29246179
[TBL] [Abstract][Full Text] [Related]
20. Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2012 Jun; 87(6):604-9. PubMed ID: 22615102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
